Placebo response in pharmacological and dietary supplement trials of autism spectrum disorder (ASD): systematic review and meta-regression analysis.
Spyridon SiafisRemzi Oğulcan ÇırayJohannes Schneider-ThomaIrene BighelliMarc KrauseAlessandro RodolicoAnna CerasoGiacomo DesteMaximilian HuhnDavid FraguasDimitris MavridisTony CharmanDeclan G M MurphyMara ParelladaCelso ArangoStefan LeuchtPublished in: Molecular autism (2020)
Placebo response in ASD was substantial and predicted by design- and participant-related factors, which could inform the design of future trials in order to improve the detection of efficacy in core symptoms. Potential solutions could be the minimization and careful selection of study sites as well as rigorous participant enrollment and the use of measurements of change not solely dependent on caregivers.
Keyphrases
- autism spectrum disorder
- systematic review
- attention deficit hyperactivity disorder
- intellectual disability
- meta analyses
- double blind
- phase iii
- palliative care
- healthcare
- randomized controlled trial
- physical activity
- health insurance
- current status
- placebo controlled
- study protocol
- working memory
- quantum dots
- sensitive detection